Japanese pharmaceutical company Shionogi & Co., Ltd. (TYO: 4507) announced that it has submitted a marketing approval application for its digital therapeutic app SDT-001 for commercialization and sale in Japan.
SDT-001 is a digital therapy app designed for the treatment of pediatric patients with Attention Deficit Hyperactivity Disorder (ADHD).
Developed by US-based digital pharmaceutical company Akili Interactive Akili, SDT-001 is a Japanese localized version of Akili.
This article is accessible to registered users. Register for free to read more. A free trial gives him one week of access to exclusive features, interviews, recaps, and commentary from some of the sharpest minds in pharma and biotech. If you are already a registered user, please log in. If your trial is over, you can subscribe here.
TRY BEFORE YOU BUY
• All the news that moves the pharmaceutical and biotech needle.
• Exclusive features, podcasts, interviews, data analysis and commentary from a global network of life science reporters.
• Receive The Pharma Letter's daily news bulletins, free forever.
become a subscriber
• Free access to industry-leading news, commentary and analysis in pharma and biotech.
• Latest information from clinical trials, conferences, M&A, licensing, financing, regulation, patents and legislation, executive appointments, commercial strategy, and financial results.
• Daily roundup of major events in pharma and biotechnology.
• Host monthly in-depth briefings on board appointments and M&A news.
• Choose from cost-effective annual packages or flexible monthly subscriptions.
